AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why AZN stock is a Buy.

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

AstraZeneca now has 16 blockbuster medicines in its portfolio with sales (product sales and alliance revenues) exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza ...

We forecast revenue declines to begin in 2026 for Farxiga and 2032 for Tagrisso. We estimate a cost of capital of 7.1%, which is consistent with those of pharmaceutical peers. We view AstraZeneca ...

Farxiga (dapagliflozin) may not be safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you ...

The medication joined the two SGLT2 inhibitors already on the market: empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) and dapagliflozin (Farxiga; AstraZeneca). Neither of the selective SGLT2 ...

AstraZeneca missed fourth-quarter estimates for earnings but beat the same for sales. Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra, Farxiga, ...